Compare Honest Company Inc (HNST) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honest Company Inc vs Illumina, Inc. — how do they compare? Honest Company Inc trades at $3.82 (market cap $426.55M), while Illumina, Inc. trades at $190.66 (market cap $27.94B). The key difference: Illumina, Inc. is far larger — about 65.5× Honest Company Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Honest Company Inc nearer its low. Which is the better fit depends on your goals.
| HNST | ILMN | |
|---|---|---|
Market Cap | $426.55M | $27.94B |
Sector | Consumer Staples | Health |
52-Week High | $4.95 | $194.33 |
52-Week Low | $2.10 | $91.00 |
Enterprise Value | $347.95M | $29.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HNST trades at $3.87, up 1.04% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting estimates, but has missed expectations in two of the last three quarters. Revenue declined to $371.32 million in 2025 from $378 million in 2024, with a net loss of $15.69 million. Positive cash flow from operations of $15.12 million and record gross margins near 34% highlight operational improvements amid challenges.
The outlook remains mixed; analyst consensus is cautious with 30% buy ratings. Upside potential exists from gross margin expansion and cost controls, but risks include persistent net losses, competitive pressures in personal care, and reliance on retail channel growth. Investor sentiment is neutral, pending sustained profitability and revenue stabilization in 2026.
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
